Physician profile
Nabil Adra
NPI 1811285893
$30,184.70
in general payments reported to CMS, 2019-2025
25 companies · $2,281 in 2025
The $2,281 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,513 · 2021: $8,812 · 2022: $6,044 · 2023: $11K · 2024: $71.98 · 2025: $2,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Travel and Lodging: $1,710 · Food and Beverage: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,825.00 |
| Travel and Lodging | $1,709.83 |
| Food and Beverage | $280.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13,021.59 | 2022-2025 | Keytruda, Welireg |
| Exelixis INC. | $4,889.55 | 2021 | |
| Celgene Corporation | $2,400.00 | 2022 | |
| Emd Serono, INC. | $2,375.00 | 2023 | |
| Genzyme Corporation | $2,246.33 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $1,530.00 | 2021-2022 | |
| Seagen INC. | $1,500.00 | 2021 | |
| Astellas Pharma Global Development | $1,395.00 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $685.00 | 2022 | |
| Amgen INC. | $91.91 | 2024-2025 | Imdelltra (Amg 757), Lumakras, Imdelltra (Amg757) |
| Janssen Scientific Affairs, LLC | $34.90 | 2023 | Erleada |
| Corcept Therapeutics | $15.42 | 2025 | Korlym |
13 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabil Adra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.